Trials / Completed
CompletedNCT00349349
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
A Single-arm, International, Multi-center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With B-cell Chronic Lymphocytic Leukemia Who Have Failed Fludarabine and Alemtuzumab
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 223 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether HuMax-CD20 (ofatumumab) is effective in the treatment of patients failing both fludarabine and alemtuzumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ofatumumab | Intravenous infusion |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2008-05-01
- Completion
- 2012-06-01
- First posted
- 2006-07-07
- Last updated
- 2014-06-04
- Results posted
- 2011-11-29
Source: ClinicalTrials.gov record NCT00349349. Inclusion in this directory is not an endorsement.